Evidence map›Paper›PMID 37679536›Full record

ArticleScientific reports2023

Prevalence of chronic kidney disease in Kazakhstan: evidence from a national cross-sectional study.

Liza Nursultanova, Kairat Kabulbayev, Dinara Ospanova, Aigul Tazhiyeva, Ubaidilla Datkhayev, Timur Saliev, Shynar Tanabayeva, Ildar Fakhradiyev

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Liza NursultanovaKazakhstan's Medical University "KSPH", Almaty, Republic of Kazakhstan.
Kairat KabulbayevS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-Bi Str., Almaty, 050020, Republic of Kazakhstan.
Dinara OspanovaAl Farabi Kazakh National University, Almaty, Republic of Kazakhstan.
Aigul TazhiyevaS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-Bi Str., Almaty, 050020, Republic of Kazakhstan.
Ubaidilla DatkhayevS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-Bi Str., Almaty, 050020, Republic of Kazakhstan.
Timur SalievS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-Bi Str., Almaty, 050020, Republic of Kazakhstan.
Shynar TanabayevaS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-Bi Str., Almaty, 050020, Republic of Kazakhstan.
Ildar FakhradiyevS.D. Asfendiyarov Kazakh National Medical University, 94, Tole-Bi Str., Almaty, 050020, Republic of Kazakhstan. fakhradiyev.i@kaznmu.kz.
Kazakh National Medical University · KZAl-Farabi Kazakh National University · KZKazakhstan Medical University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To date, there have been no large-scale national studies of the prevalence of chronic kidney disease in Kazakhstan. It includes the research based on the analysis of the estimated glomerular filtration rate (eGFR). The aim of this study was to investigate the population prevalence of CKD and associated risk factors in Kazakhstan. The cross-sectional study consisted of a nationally representative sample of n = 6 720 adults aged 18 to 69 from 14 regions and 3 major cities in Kazakhstan. The study covered the period from October 2021 to May 2022. The WHO STEPS questionnaire was used for the survey. For the diagnosis of CKD, creatinine levels in collected blood samples were measured to assess eGFR. Demographic characteristics were collected and studied. The total and adjusted prevalence of factors associated with the presence of CKD were calculated and analysed using logistic regression. 73.5% (n = 4940) of participants had normal eGFR, while 25.2% (n = 1695) had mild CKD (eGFR = 60-89 mL/min/1.7 m

Indexed as

Renal Insufficiency, ChronicAdultCitiesCross-Sectional StudiesHumansKazakhstanPrevalence

Identifiers

PMID37679536
PMCPMC10485008
OpenAlexW4386514666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.